Three agents no better than two for advanced NSCLC

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1449, 2004-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Two is better than one for pain relief in migraine

Inpharma, Vol. 1, Iss. 1514, 2005-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Combining Anti-Epidermal Growth Factor Receptor (EGFR) and Anti-Angiogenic Strategies in Advanced NSCLC: We Should have Known Better…

Current Pharmaceutical Design, Vol. 20, Iss. 24, 2014-05 ,pp. : 3901-3913

Bentham Science Publishers

Access to resources Recommend Favorite

Docetaxel + cisplatin active in advanced NSCLC

Inpharma, Vol. 1, Iss. 1478, 2005-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Oxaliplatin plus paclitaxel in advanced NSCLC

Inpharma, Vol. 1, Iss. 1444, 2004-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Motesanib and advanced NSCLC: experiences and expectations

By Raghav Kanwal Pratap Singh Blumenschein George R

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 6, 2011-06 ,pp. : 859-869

Informa Healthcare

Access to resources Recommend Favorite